雲頂新耀-B(01952.HK)公佈中期業績:收入激增至3.015億元,毛利率大幅提升
格隆匯8月28日丨雲頂新耀-B(01952.HK)公佈中期業績,截至2024年6月30日止六個月,在依嘉®及耐賦康®的推動下,集團錄得收入人民幣3.015億元,截至2023年6月30日止六個月則為人民幣890萬元。期內毛利達到人民幣2.31億元,上年同期毛利為人民幣557.7萬元。毛利率由截至2023年6月30日止六個月的62.7%增加至截至2024年6月30日止六個月的76.6%,及毛利率(不包括無形資產攤銷)由截至2023年6月30日止六個月的62.7%增加至截至2024年6月30日止六個月的83.0%,主要由於新產品的上市。
2024年,公司的業務拓展戰略仍着重於具有差異化、高價值治療領域的同類首創或同類最佳資產,包括腎臟疾病、自身免疫性疾病和抗感染等領域。基於公司已建立的高效精幹的商業化模式,公司將更着眼於引進商業化階段產品,以利用公司經驗豐富且高效的銷售團隊,實現協同效應最大化,提升運營效率。公司相信,通過有效的管線搭建,公司將持續鞏固在重點治療領域的領導地位,以推動本公司現金流的增長,並提升公司的盈利能力。在“出海”合作方面,公司基於擁有完整知識產權的mRNA平台,正在開發多款非常前沿的腫瘤治療性疫苗項目,有望在早期階段為公司帶來全球合作機會,進一步為股東創造價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.